JP2014533278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533278A5 JP2014533278A5 JP2014541312A JP2014541312A JP2014533278A5 JP 2014533278 A5 JP2014533278 A5 JP 2014533278A5 JP 2014541312 A JP2014541312 A JP 2014541312A JP 2014541312 A JP2014541312 A JP 2014541312A JP 2014533278 A5 JP2014533278 A5 JP 2014533278A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- antibody
- her3
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 50
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 50
- 239000003446 ligand Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 230000026731 phosphorylation Effects 0.000 claims description 16
- 238000006366 phosphorylation reaction Methods 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 10
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 230000035578 autophosphorylation Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 36
- 230000002401 inhibitory effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557672P | 2011-11-09 | 2011-11-09 | |
| US61/557,672 | 2011-11-09 | ||
| PCT/US2012/064381 WO2013071058A1 (en) | 2011-11-09 | 2012-11-09 | Her3 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533278A JP2014533278A (ja) | 2014-12-11 |
| JP2014533278A5 true JP2014533278A5 (enExample) | 2015-12-24 |
| JP6149042B2 JP6149042B2 (ja) | 2017-06-14 |
Family
ID=48290585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541312A Expired - Fee Related JP6149042B2 (ja) | 2011-11-09 | 2012-11-09 | Ｈｅｒ３抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9637543B2 (enExample) |
| EP (1) | EP2788377B1 (enExample) |
| JP (1) | JP6149042B2 (enExample) |
| CN (1) | CN104011079B (enExample) |
| AU (1) | AU2012335543C1 (enExample) |
| CA (1) | CA2855298A1 (enExample) |
| WO (1) | WO2013071058A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200793T1 (hr) | 2011-05-09 | 2020-10-16 | Mayo Foundation For Medical Education And Research | Liječenje raka |
| EP3608340A1 (en) | 2011-11-23 | 2020-02-12 | Medlmmune, LLC | Binding molecules specific for her3 and uses thereof |
| WO2013084147A2 (en) * | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| EP3154586B1 (en) | 2014-06-13 | 2020-05-27 | Mayo Foundation for Medical Education and Research | Treating lymphomas |
| MX2016016617A (es) | 2014-06-16 | 2017-03-23 | Mayo Foundation | Tratamiento de mielomas. |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| WO2016059602A2 (en) * | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| CA3018340A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| KR20220151022A (ko) | 2016-09-01 | 2022-11-11 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| MX2019002473A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Métodos y composiciones para el direccionamiento de cánceres de células t. |
| CA3035653A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CA3035655A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| EP3559042A4 (en) * | 2016-12-22 | 2020-11-25 | Icahn School of Medicine at Mount Sinai | ANTI-LILRB3 ANTIBODIES AND METHOD OF USING THEREOF |
| CN117500832A (zh) * | 2021-06-15 | 2024-02-02 | 北京先通生物医药技术有限公司 | 抗her3抗体、含有该抗体的抗体药物缀合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP1728802A3 (en) * | 1996-03-27 | 2006-12-13 | Genentech, Inc. | ErbB3 antibodies |
| AUPP380498A0 (en) | 1998-05-29 | 1998-06-25 | Biomolecular Research Institute Limited | Egf receptor agonists and antagonists |
| AU2002345673B2 (en) * | 2001-06-13 | 2007-04-26 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| BRPI0808055A2 (pt) | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
| AU2009281721A1 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| SG178509A1 (en) * | 2009-08-21 | 2012-04-27 | Merrimack Pharmaceuticals Inc | Antibodies against the ectodomain of erbb3 and uses thereof |
| MY162825A (en) * | 2010-08-20 | 2017-07-31 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| CN103189392B (zh) * | 2010-10-18 | 2016-03-30 | 米迪亚制药有限责任公司 | ErbB3结合抗体 |
-
2012
- 2012-11-09 WO PCT/US2012/064381 patent/WO2013071058A1/en not_active Ceased
- 2012-11-09 AU AU2012335543A patent/AU2012335543C1/en not_active Ceased
- 2012-11-09 EP EP12847223.0A patent/EP2788377B1/en not_active Not-in-force
- 2012-11-09 CN CN201280064525.0A patent/CN104011079B/zh not_active Expired - Fee Related
- 2012-11-09 US US14/357,524 patent/US9637543B2/en not_active Expired - Fee Related
- 2012-11-09 JP JP2014541312A patent/JP6149042B2/ja not_active Expired - Fee Related
- 2012-11-09 CA CA2855298A patent/CA2855298A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533278A5 (enExample) | ||
| Xuhong et al. | Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer | |
| Passardi et al. | Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial | |
| Polivka et al. | Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme | |
| Aysola et al. | Triple negative breast cancer–an overview | |
| Dong et al. | MET-targeted therapies and clinical outcomes: a systematic literature review | |
| Lin et al. | EGFR-TKI resistance in NSCLC patients: mechanisms and strategies | |
| Rexer et al. | Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells | |
| Chivu-Economescu et al. | New therapeutic options opened by the molecular classification of gastric cancer | |
| Duffaud et al. | Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials | |
| NZ720955A (en) | Activin-actrii antagonists and uses for increasing red blood cell levels | |
| AR065092A1 (es) | TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS | |
| Lee et al. | Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma | |
| EA201100425A1 (ru) | Производные пиколинамида в качестве ингибиторов киназы | |
| JP2018508593A5 (enExample) | ||
| NZ715177A (en) | Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same | |
| Criscitiello et al. | Targeted therapies in breast cancer: are heart and vessels also being targeted? | |
| Cheraghchi-Bashi et al. | A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway | |
| Zhang et al. | The prognostic significance of combining VEGFA, FLT1 and KDR mRNA expressions in brain tumors | |
| Fukuda et al. | Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel | |
| Grünwald et al. | The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors–is there more to come? | |
| Friedlander et al. | Advances in targeted therapy for melanoma | |
| Wu et al. | Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non‐Hodgkin lymphoma | |
| RU2017101809A (ru) | Способы лечения рака и профилактики устойчивости рака к лекарственному средству | |
| Li et al. | The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials |